Prescient Therapeutics Ltd
Price Chart
OHLC · volume · moving averages
Market Statistics
Today's trading range
Valuation
Fundamental multiples
Trading Activity
Volume & order book
Performance
Returns across timeframes
Technical Indicators
Momentum & moving averages
— From the desk
Latest News
Prescient Therapeutics’ First-in-Class Cancer Drug Approaching a Pivotal Moment
Prescient Therapeutics’ PTX-100 nears pivotal Phase 2a in CTCL; 100% clinical benefit in Phase 1b potential big-pharma partner as first-in-class GGT-1/RAS hit.
Prescient Therapeutics Moves Advanced PTX-100 Cutaneous T-Cell Lymphoma Therapy Closer to Commercialisation
Prescient Therapeutics (ASX: PTX) is fast emerging as the newest developer of an advanced cancer drug to meet a significant market need, potentially converting years of work into billions of dollars. The company’s lead candidate PTX-100 is now in its all-important Phase 2 clinical trials. It is at this stage where data read-outs can provide […]
Prescient Therapeutics Confirms First US Site for PTX-100 Phase 2a Refractory Cutaneous T-Cell Lymphoma Trial
Oncology biotech Prescient Therapeutics (ASX: PTX) has announced the completion of its first US site visit for its Phase 2a trial of PTX-100 for patients with refractory or relapsed cutaneous T-cell lymphoma (r/r CTCL). The Massey Comprehensive Cancer Centre at Virginia Commonwealth University – ranked as one of the top cancer research centres in the […]
Prescient Therapeutics’ PTX-100 Progresses to Phase 2a Trials after Outstanding Phase 1b Results
Clinical-stage oncology company Prescient Therapeutics (ASX: PTX) is looking to disrupt a US$1.8 billion market on the back of outstanding Phase 1b clinical trial data for lead candidate PTX-100 to treat cutaneous T-cell lymphoma (CTCL). Now in its Phase 2a trial, the advanced drug has delivered a 64% tumour halt or shrinkage in patients with […]